A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

NCT05573802 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Neoplasms
Neoplasm, Plasma Cell
Gammopathy, Monoclonal
Paraproteinemias
Blood Protein Disorders
Haematologic Disease
Corneal Disease

Interventions

DRUG: Belantamab Mafodotin-Blmf
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Nirogacestat

Sponsor

Hellenic Society of Hematology

Collaborators

[object Object]